CMS Decentralized Trials & Gene Therapy Frameworks

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The policy shifts are accelerating.

MarcusSame here. We're looking at CMS's proposed Medicare Advantage star ratings methodology shift — why the patient experience focus matters for access. Then FDA's decentralized clinical trials draft guidance — implications for RWE generation. And ICER's new framework for gene therapies in rare diseases — addressing the cost-effectiveness challenge.

SaraThat second one is particularly interesting to me — the decentralized trials guidance could reshape RWE acceptance, but I wonder if it adequately addresses payer concerns about data integrity in real-world settings.

MarcusExactly. Let's get into it.

MarcusCMS has proposed significant changes to Medicare Advantage star ratings, emphasizing patient experience surveys and social determinants of health. This directly impacts plan payments and member retention, making it a market access lever. The shift toward patient-centric metrics signals a broader trend in value assessment.

SaraThat's one read — but I'd frame it slightly differently. The increased weight on member experience surveys is problematic. These are volatile metrics influenced by factors outside plan control, like marketing or cultural attitudes. The part that gives me pause is whether this actually improves care quality or just creates new administrative burdens for plans.

MarcusThat's fair, though CMS is clearly trying to align ratings with what patients experience. The new care coordination measures address fragmentation, which is a known pain point. But you're right about the surveys—methodological rigor will be crucial. The key question is whether this leads to better outcomes or just more complexity in formulary decisions.

SaraAnd what's striking here is the downstream effect on drug access. If plans prioritize star ratings, they might be more open to covering therapies that improve patient experience. But if the methodology becomes too unpredictable, it could create uncertainty for manufacturers. This is one of those stories where the intent is progressive, but the implementation risks unintended consequences.

MarcusExactly. And we'll be watching the comment period and final rule. The stakes are high—this could set precedents for private payers too. For HEOR teams, it means preparing evidence packages that demonstrate impact on these new metrics.

SaraRight, and from the payer side, there's also the opportunity cost angle. Resources diverted to chasing star ratings might detract from managing high-cost drugs. That's a trade-off we need to monitor closely.

SaraThe FDA's draft guidance on decentralized clinical trials emphasizes telehealth, remote monitoring, and local labs. This is a game-changer for accelerating drug development by reducing patient burden. But I'm concerned about how this translates to HTA submissions—will decentralized data be considered equivalent to traditional trial evidence?

MarcusThat's a thoughtful question. The FDA is signaling that decentralized elements can maintain data integrity through robust electronic systems. What strikes me is the patient-centric angle, aligning with the broader RWE movement. But the guidance does stress methodological rigor—it's not a lower-bar approach. The real question is whether HTA bodies will adapt their evidence hierarchies.

SaraI'd push back slightly. The lack of clarity on HTA acceptance is the sticking point. Payers remain skeptical about RWE for primary endpoints, especially for high-stakes decisions. This guidance might help, but it doesn't solve the fundamental evidence hierarchy problem. We've seen this before with adaptive designs—regulatory acceptance doesn't always translate to payer acceptance.

MarcusThat's fair. But the FDA's move could create momentum. If decentralized trials become the norm, it might force HTA bodies to evolve. The key is transparency in data collection and analysis. For HEOR teams, this means preparing hybrid evidence packages that blend traditional and decentralized data.

SaraAnd what about the practical challenges? Remote monitoring requires reliable infrastructure, which isn't evenly distributed. Patient adherence without in-person supervision could be an issue. This is one of those stories where the potential is enormous, but real-world implementation might be uneven.

MarcusExactly. The FDA acknowledges this, requiring sponsors to justify their approach. It's about thoughtful implementation, not permissiveness. We'll see how this plays out in submissions—especially for rare diseases where patient recruitment is difficult.

SaraFrom a payer perspective, we need to see if this leads to faster access without compromising evidence quality. The jury's still out.

MarcusICER has released a new framework for evaluating gene therapies in rare diseases, emphasizing long-term outcomes and patient perspectives. This is critical given the one-time costs and complex value propositions of these therapies. It provides clearer guidance for manufacturers on structuring evidence submissions.

SaraThat's one read — but I'd frame it slightly differently. The framework is a step forward, but I wonder if it fully addresses the budget impact question. Gene therapies create massive one-time expenditures that traditional cost-effectiveness models struggle with. ICER mentions sustainability, but it doesn't provide concrete solutions for system-wide affordability. That's a gap.

MarcusThat's a valid point. The framework does include a new 'sustainability and affordability' domain, but you're right—it's not a silver bullet. The real test will be how this translates to coverage decisions. Payers are still grappling with the financial risk of these therapies. The framework acknowledges the need for RWE to confirm long-term outcomes, which is essential given the novelty.

SaraAnd what's interesting here is the international angle. ICER's framework could influence other HTA bodies, but each jurisdiction has different budget constraints. In the US, the IRA negotiation process adds another layer of complexity. This is one of those stories where evidence is evolving faster than policy frameworks can adapt.

MarcusExactly. For HEOR teams, this means planning for long-term follow-up studies and being transparent about uncertainties. The framework signals that ICER is trying to balance innovation with affordability, but the operationalization remains challenging.

SaraRight, and from the payer side, we'll be watching how this framework is applied. If it leads to more consistent decisions, that's positive. But if it doesn't address the fundamental affordability issue, it might not change much on the ground.

SaraNICE has updated its guidance on using real-world evidence for technology appraisals, expanding the circumstances where RWE can be used. This fills evidence gaps for innovative technologies with limited trial data. The updated guidance stresses methodological rigor and transparency in data sources.

MarcusThat's a thoughtful take. NICE's move reflects broader RWE acceptance, but it raises the bar for manufacturers. The guidance provides clarity, but it also requires investment in high-quality RWE generation. For HEOR teams, this means designing studies that meet NICE's evolving standards.

SaraI'd push back slightly. The part that gives me pause is potential inconsistency. If RWE is applied differently across appraisals, it creates unpredictability. NICE says it will use RWE only when 'appropriate,' but that definition is subjective. This could lead to variability in how technologies are evaluated, which is problematic for manufacturers.

MarcusThat's fair. The guidance does include criteria—like evidence gaps or long-term outcomes—but subjectivity is a real concern. However, NICE is trying to balance innovation with evidence quality. The key is transparency in decision-making. For submissions, it means being prepared to justify RWE methodology thoroughly.

SaraAnd what's striking here is the timing. With more innovative technologies entering the market, RWE is becoming indispensable. But payers are still building trust in its reliability. This is one of those stories where the potential is great, but implementation needs careful calibration.

MarcusExactly. The evolution of RWE in HTA is something we'll be watching closely. It represents a fundamental shift in how we generate and assess evidence.

SaraAbsolutely.

SaraA lot to think about today. I'll be watching how CMS finalizes the Medicare Advantage star ratings methodology—its impact on access could be significant.

MarcusSame — and for me the thread running through today is the growing emphasis on patient-centric data, whether from decentralized trials, patient-reported outcomes, or RWE. It's reshaping how we define value.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.